Day 3: **Wednesday, Feb 25**

8.30 – 10.00   Atrial cardiopathy – Chairs: *Julia Aulin, Ana Catarina Fonseca*

AF burden revisited: biomarker and treatment target
Märit Jensen, Hamburg

Plasma proteomic profiles linked to post-stroke myocardial injury
Jan Scheitz, Berlin / Selected abstract talk

Biomarker-guided patient selection for anticoagulation trials
Hooman Kamel, New York

Symmetric dimethylarginine for risk stratification of cardioembolic stroke etiology
Gerrit Große, Basel / Selected abstract talk

10.00 – 10.30   Coffee break

10.30 – 12.20   Vascular disease – Chairs: *Annaelle Zietz, Gerrit Grosse*

Imaging-based selection of patients for intervention and secondary prevention trials
Anna Kopczak, Munich

Inflammatory mediators of stroke risk
John McCabe, Dublin

TNF signalling and risk of stroke
Jane Buckley & Stephen Brennan, Dublin / Selected abstract talk

Paired plasma-thrombus proteomics identify inflammation as a key determinant of thrombus composition
Yasin Eshraghi, Munich / Selected abstract talk

FXI inhibition: biology, genetic epidemiology, biomarkers, and clinical trial data – bridging the gap to personalized medicine
Christian Ruff, Boston

12.20 – 13.00   **Closing lecture –** Chair: Johanna Ospel
From bench-to-bedside: genetics for precision medicine in vascular disease
Pradeep Natarajan, Boston

13.00 – 14.00   Farewell & lunch

Organizers:

John McCabe
University College Dublin
Ireland
john.mccabe@ucd.ie

Johanna Ospel
University of Calgary
Canada
johanna.ospel@ucalgary.ca

Steffen Tiedt
Institute for Stroke & Dementia Research
LMU Hospital Munich, Germany
steffen.tiedt@med.uni-muenchen.de

Supported by:

Merck   Quanterix®   CSL

Endorsed by:

ESO EUROPEAN STROKE ORGANISATION — ENDORSED

Organized by:

Institute for Stroke and Dementia Research (ISD)

ISCBFM — International Society for Cerebral Blood Flow & Metabolism

UNIVERSITY OF CALGARY

DFG Deutsche Forschungsgemeinschaft

ESMINT — ENDORSED

LMU KLINIKUM

2nd **BIOSTROKE Meeting**

Feb 23 – 25, 2026

biostroke

Venue:

Hohenkammer Castle

Hohenkammer, Germany

Program

Day 1: **Monday, Feb 23**

Venue:
Hohenkammer Castle
Schlossstrasse 18 – 25, 5411 Hohenkammer, Germany
https://www.schlosshohenkammer.de/

Schloss Hohenkammer

12.00 – 13.00	Registration and light lunch in the lobby
13.00 – 13.05	Welcome note: *John McCabe, Johanna Ospel, Steffen Tiedt*
13.05 – 15.00	Intracerebral hemorrhage – Chairs: *María Alonso de Leciñana, Umberto Pensato*

Perspectives on the high burden of ICH – what do we know?
Karin Klijn, Nijmegen

ICH progression: pathophysiological concepts and biomarkers
Neshika Samarasekera, Edinburgh

Evolution patterns of spot sign to stratify intracerebral hemorrhage expansion risk
Umberto Pensato, Milan / Selected abstract talk

Brain-derived tau for assessing neuronal injury in intracerebral hemorrhage
Naomi Vlegels, Munich / Selected abstract talk

Diagnostic and prognostic biomarkers for CAA
Marieke Wermer, Groningen

15.00 – 15.30	Coffee break
15.30 – 17.30	Novel technologies and concepts – Chairs: *Susanne Wegener, Beom Joon Kim*

The gut microbiome in stroke: biomarker and treatment target?
Corinne Benakis, Munich

Circulating metabolites are biomarker candidates for stroke risk prediction – results from the BiomarCaRE consortium
Märit Jensen, Hamburg / Selected abstract talk

The glymphatic system in stroke: biomarker and treatment target?
Lauren Hablitz, Rochester

Portable MRI: can serial MR imaging with portable devices guide clinical management?
Taylor Kimberly, Boston

Association between time and severe hypoperfusion with risk of hemorrhagic transformation in stroke patients
Umberto Pensato, Milan / Selected abstract talk

17.30 – 18.30	**Keynote lecture** – Chair: *Steffen Tiedt* Blood testing to track organ health and ageing *Tony Wyss-Coray, Stanford*
18.30 – 19.30	Welcome reception
19.30	Dinner

Day 2: **Tuesday, Feb 24**

8.30 – 10.30	Prehospital care – Chairs: *Laura Gioia, Heinrich Audebert*

Troponin to guide hospital admission – a cardiologist's perspective on prehospital biomarkers
Niels van Royen, Nijmegen

Prehospital detection of LVO and ICH – when & where does it matter?
Natalia Perez de la Ossa, Barcelona

Berlin prehospital collection of biosamples in stroke and other emergencies – B_PRECISE
Kian Röhrs, Berlin / Selected abstract talk

Clinical scales and molecular biomarkers for prehospital stroke triage
Chris Price, Newcastle

Prehospital detection of large vessel occlusion using biomarkers and clinical variables in mobile stroke units
Leire Azurmendi Gil, Geneva / Selected abstract talk

10.30 – 11.00	Coffee break
11.00 – 13.00	Stroke progression and recovery – Chairs: *Naomi Vlegels, Bastian Cheng*

Imaging-based selection of patients for acute stroke trials: challenges and perspectives
Frédéric Clarençon, Paris

Surrogate markers of treatment effects in acute stroke trials
Michael Hill, Calgary

Integrated multi-omics factor analysis identifies early molecular signatures of brain injury in ischemic stroke
Cao Wei, Munich / Selected abstract talk

Biomarkers for motor recovery: predicting outcomes and guiding rehabilitation in stroke
Cathy Stinear, Auckland

Plasma NfL and GFAP in acute stroke: clinical determinants and prognostic value for 5-year cognitive outcomes
Jule Filler, Munich / Selected abstract talk

13.00 – 14.00	Lunch
	BIOSTROKE session
14.00 – 14.45	**Keynote lecture** – Chair: *John McCabe* How to build a successful biomarker consortium – insights from BiomarCaRE *Tanja Zeller, Lübeck*
14.45 – 16.15	Working groups breakout-session
16.15 – 17.30	International collaboration at scale in biomarker research: benefits, tips, and pitfalls. Chair: *John McCabe*

Rapid communications:

Sample sharing initiatives at scale: how I did it and what I should have considered
Gerrit Grosse, Basel & Steffen Tiedt, Munich

Imaging data sharing across centers: practical tips, technical & logistical considerations
Susanne Wegener, Zurich

The International Stroke Genetics Consortium: history, structures, and success.
Israel Fernandez, Barcelona

Embedding biomarker substudies in RCTs: balancing opportunity with feasibility
Michael D. Hill, Calgary

Data standardisation in stroke biomarker research: why it matters and how can we do better?
John McCabe, Dublin & Steffen Tiedt, Munich & Johanna Ospel, Calgary

17.30 – 19.00	Poster session
19.00	Dinner